MILFORD, Mass., March 8 /PRNewswire-FirstCall/ -- Waters Corporation and Bruker BioSciences Corporation , Billerica, MA, have entered into a collaboration agreement to provide greater integration and connectivity between Waters(R) ACQUITY Ultra Performance LC(TM) (UPLC(TM)) system and Bruker’s mass spectrometry (MS) and nuclear magnetic resonance (NMR) products. The collaboration will allow direct support of Waters ACQUITY UPLC System in Bruker’s HyStar(TM) software thus unifying control and results management to seamlessly combine these complementary technologies. The products of both companies play an important role in the discovery, development, and manufacture of pharmaceuticals, processed foods, beverages, personal care products, and in environmental and food safety laboratories.
“Scientists are always looking for a competitive edge and many have experienced the advantages of using UPLC with MS,” said Rohit Khanna, Ph.D., Vice President -- Worldwide Marketing, Waters Corporation. “Combining UPLC with mass spectrometry brings scientists measurable improvements in performance and in the overall quality of information they obtain from their LC/MS and LC/NMR analyses resulting in improved decision-making, increased productivity and reduced business risk.”
UPLC and MS -- A Natural Fit
Mass spectrometry results are highly-dependent on the liquid chromatography separation preceding ionization and confirmatory analysis in the mass spectrometer.
Compared to conventional high performance liquid chromatography (HPLC), UPLC results are significantly better -- peaks are narrower and sharper, signal-to-noise ratios are higher, peak capacity is greater, run times are shorter -- which are all key factors in reducing the effects of ion suppression and enhancing the performance of virtually any mass spectrometer, thus bringing laboratories new levels of efficiency. For Waters and Bruker customers, the seamless combination of UPLC technology with mass spectrometry promises to bring their laboratories more information per unit of time resulting in greater productivity.
About Waters Corporation (http://www.waters.com)
Waters Corporation holds worldwide leading positions in three complementary analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis. These market segments account for $4.5 - $5.0 billion of the overall $20+ billion analytical instrumentation market.
Waters, ACQUITY UPLC, ACQUITY Ultra Performance LC, UPLC, and Ultra Performance LC are trademarks of Waters Corporation. HyStar is a trademark of Bruker Biosciences Corporation.
Certain statements contained herein are forward looking. Many factors could cause actual results to differ from these statements, including delays in product introductions, loss of market share through competition, introduction of competing products by other companies, pressures on prices from competitors and/or customers, regulatory obstacles to new product introductions, lack of acceptance of new products, changes in the healthcare market and the pharmaceutical industry, changes in distribution of the Company’s products, and foreign exchange fluctuations. Such factors are discussed in detail in the Company’s filings with the Securities and Exchange Commission and, in particular, the Company’s Annual Report on Form 10-K for the year ended December 31, 2005.
Investor Contact: Gene Cassis Vice President, Investor Relations +1-508-482-2349 Media Contact: Brian J. Murphy Corporate Communications +1 508-482-2614
Waters Corporation
CONTACT: Gene Cassis, Vice President, Investor Relations, +1-508-482-2349,Brian J. Murphy, Corporate Communications, +1-508-482-2614, both of WatersCorporation
Web site: http://www.waters.com/
